[go: up one dir, main page]

AR030541A1 - Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica - Google Patents

Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica

Info

Publication number
AR030541A1
AR030541A1 ARP000106418A ARP000106418A AR030541A1 AR 030541 A1 AR030541 A1 AR 030541A1 AR P000106418 A ARP000106418 A AR P000106418A AR P000106418 A ARP000106418 A AR P000106418A AR 030541 A1 AR030541 A1 AR 030541A1
Authority
AR
Argentina
Prior art keywords
manufacture
pharmaceutical formulation
acids
amyinopropylphosphinic
medicines
Prior art date
Application number
ARP000106418A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0003640A external-priority patent/SE0003640D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR030541A1 publication Critical patent/AR030541A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/48—Phosphonous acids [RP(OH)2] including [RHP(=O)(OH)]; Thiophosphonous acids including [RP(SH)2], [RHP(=S)(SH)]; Derivatives thereof
    • C07F9/4808—Phosphonous acids [RP(OH)2] including [RHP(=O)(OH)]; Thiophosphonous acids including [RP(SH)2], [RHP(=S)(SH)]; Derivatives thereof the acid moiety containing a substituent or structure which is considered as characteristic
    • C07F9/4816—Acyclic saturated acids or derivatices which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Acidos aminopropilfosfínicos que tiene la formula (1) donde R1 representa hidrogeno, R2 representa hidroxi, fluor, o un grupo oxo; R3 representa hidrogeno; R4 representa hidrogeno; y las sales farmacéuticamente aceptables, solvatos y estereoisomeros de los mismos, con la excepcion del racemato del ácido (3-amino-2-hidroxipropil)fosfínico, su utilizacion para la manufactura de medicamentos y formulacion farmacéutica.
ARP000106418A 1999-12-09 2000-12-04 Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica AR030541A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904508A SE9904508D0 (sv) 1999-12-09 1999-12-09 New compounds
SE0003640A SE0003640D0 (sv) 2000-10-09 2000-10-09 New compounds

Publications (1)

Publication Number Publication Date
AR030541A1 true AR030541A1 (es) 2003-08-27

Family

ID=26655259

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106418A AR030541A1 (es) 1999-12-09 2000-12-04 Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica

Country Status (33)

Country Link
US (5) US6576626B2 (es)
EP (2) EP1240172B1 (es)
JP (2) JP3914435B2 (es)
KR (1) KR100689144B1 (es)
CN (1) CN1198832C (es)
AR (1) AR030541A1 (es)
AT (1) ATE282043T1 (es)
AU (1) AU780459B2 (es)
BR (1) BR0016253A (es)
CA (1) CA2397583C (es)
CZ (1) CZ20021983A3 (es)
DE (1) DE60015796T2 (es)
DK (1) DK1240172T3 (es)
EE (1) EE05067B1 (es)
ES (1) ES2230174T3 (es)
HK (1) HK1048321B (es)
HU (1) HUP0300301A3 (es)
IL (2) IL149840A0 (es)
IS (1) IS2231B (es)
MX (1) MXPA02005536A (es)
MY (1) MY125414A (es)
NO (1) NO329595B1 (es)
NZ (1) NZ519376A (es)
PL (1) PL201789B1 (es)
PT (1) PT1240172E (es)
RU (1) RU2260595C2 (es)
SE (1) SE9904508D0 (es)
SI (1) SI1240172T1 (es)
SK (1) SK286904B6 (es)
TW (1) TWI228510B (es)
UA (1) UA71649C2 (es)
WO (1) WO2001042252A1 (es)
ZA (1) ZA200204127B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319095B2 (en) * 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
JP2004521898A (ja) * 2001-02-05 2004-07-22 カム、マイケル・アルバート 食道運動性疾患及び胃食道逆流性疾病の治療方法
AR033779A1 (es) * 2001-06-08 2004-01-07 Astrazeneca Ab Compuestos utiles en la enfermedad de reflujo
SE0201939D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination
SE0201940D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
SE0402462D0 (sv) * 2004-10-08 2004-10-08 Astrazeneca Ab New process
WO2006050471A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US7494985B2 (en) 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
US20060160777A1 (en) * 2004-12-27 2006-07-20 Anders Lehmann New use of GABAbeta receptor agonists
EP1966154A4 (en) 2005-12-23 2011-01-26 Astrazeneca Ab IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
BRPI0620464A2 (pt) 2005-12-23 2011-11-16 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, método para o tratamento de uma doença
US7585996B2 (en) 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
JP5520816B2 (ja) * 2007-05-04 2014-06-11 アストラゼネカ・アクチエボラーグ アミンおよびアミンオキシドで開始するアルキルホスフィン酸の合成方法
US20100317626A1 (en) * 2007-07-25 2010-12-16 Astrazeneca Ab The Use Of (3-Amino-2-Fluoropropyl) Phosphinic Acid For Treatment Of NERD
PE20091310A1 (es) * 2007-12-21 2009-09-30 Astrazeneca Ab Nueva forma cristalina b del acido (2r)-(3-amino-2-fluoropropil)fosfinico
PE20091176A1 (es) * 2007-12-21 2009-09-03 Astrazeneca Ab Nueva forma cristalina c del acido (2r)-(3-amino-2-fluoropropil)fosfinico
EP2235026A4 (en) * 2007-12-21 2011-08-17 Astrazeneca Ab NEW PROCESS FOR THE PREPARATION OF (2R) - (3-AMINO-2-FLUORO-PROPYL) PHOSPHIC ACID FORM A
WO2009145716A1 (en) * 2008-05-28 2009-12-03 Astrazeneca Ab New pharmaceutical formulation useful in gerd therapy
WO2010051883A1 (de) 2008-11-05 2010-05-14 Clariant International Ltd Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels allylalkoholen/acroleinen und ihre verwendung
DE102008056341A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von monoaminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
ES2525550T3 (es) 2008-11-07 2014-12-26 Clariant Finance (Bvi) Limited Procedimiento para la preparación de ácidos, ésteres y sales dialquilfosfínicos mediante derivados del ácido acrílico y su uso
CN102171226B (zh) 2008-11-11 2015-02-11 科莱恩金融(Bvi)有限公司 利用烯丙基化合物制备单烯丙基官能化的二烷基次膦酸、其盐或酯的方法以及它们的用途
DE102008060035A1 (de) * 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060535A1 (de) 2008-12-04 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylether und ihre Verwendung
DE102008063642A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monocarboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Alkylenoxiden und ihre Verwendung
DE102008063668A1 (de) 2008-12-18 2010-07-01 Clariant International Limited Verfahren zur Herstellung von Alkylphosponsäuren, -estern und -salzen mittels Oxidation von Alkylphosphonigsäuren und ihre Verwendung
DE102008063627A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monohydroxyfunktionalisierten Dialkylphosphinsäuren,-estern und -salzen mittels Ethylenoxid und ihre Verwendung
KR101697948B1 (ko) 2008-12-18 2017-01-19 클라리언트 파이넌스 (비브이아이)리미티드 아세틸렌을 사용하는 에틸렌디알킬포스핀산, 에틸렌디알킬포스핀산 에스테르 및 에틸렌디알킬포스핀산 염의 제조방법 및 이의 용도
DE102008064003A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449046A (de) 1963-07-09 1967-12-31 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
GB8425872D0 (en) * 1984-10-12 1984-11-21 Ciba Geigy Ag Chemical compounds
WO1987004077A1 (en) 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
US4740332A (en) * 1986-05-12 1988-04-26 E. R. Squibb & Sons, Inc. Process for preparing phosphonous acids
GB8820266D0 (en) 1988-08-26 1988-09-28 Smith Kline French Lab Compounds
US5281747A (en) 1989-05-13 1994-01-25 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
GB8911017D0 (en) 1989-05-13 1989-06-28 Ciba Geigy Ag Substituted aminoalkylphosphinic acids
US5567840A (en) 1989-05-13 1996-10-22 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
US5006560A (en) 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
IL98502A (en) * 1990-06-22 1998-04-05 Ciba Geigy Ag Aminoalkane phosphinic acid derivatives, process for their preparation and pharmaceutical compositions containing them
FR2663934B1 (fr) 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
GB9125615D0 (en) * 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
AU662404B2 (en) * 1992-05-08 1995-08-31 Novartis Ag Novel N-aralkyl- and N-heteroaralkyl-aminoalkanephosphinic acids
FR2722192A1 (fr) 1994-07-06 1996-01-12 Adir Nouveaux derives de l'acide 4-amino butyrique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9420784D0 (en) 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
SE9603408D0 (sv) 1996-09-18 1996-09-18 Astra Ab Medical use
US7319095B2 (en) * 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
SE9904507D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds

Also Published As

Publication number Publication date
ES2230174T3 (es) 2005-05-01
SK286904B6 (sk) 2009-07-06
TWI228510B (en) 2005-03-01
US7034176B2 (en) 2006-04-25
CN1409716A (zh) 2003-04-09
JP2006306885A (ja) 2006-11-09
EP1484333A1 (en) 2004-12-08
BR0016253A (pt) 2002-08-27
KR100689144B1 (ko) 2007-03-08
MXPA02005536A (es) 2004-09-10
SK7642002A3 (en) 2002-12-03
EE200200286A (et) 2003-08-15
NO20022728L (no) 2002-08-07
NZ519376A (en) 2003-11-28
HK1048321B (en) 2005-09-30
US7807658B2 (en) 2010-10-05
KR20020060992A (ko) 2002-07-19
WO2001042252A1 (en) 2001-06-14
RU2002113909A (ru) 2004-01-10
PT1240172E (pt) 2005-02-28
IL149840A (en) 2006-04-10
PL364795A1 (en) 2004-12-13
HUP0300301A2 (hu) 2003-06-28
DE60015796D1 (de) 2004-12-16
HUP0300301A3 (en) 2008-12-29
SE9904508D0 (sv) 1999-12-09
CN1198832C (zh) 2005-04-27
NO20022728D0 (no) 2002-06-07
EE05067B1 (et) 2008-08-15
DK1240172T3 (da) 2005-02-14
ZA200204127B (en) 2003-08-25
MY125414A (en) 2006-07-31
RU2260595C2 (ru) 2005-09-20
US20020156053A1 (en) 2002-10-24
JP3914435B2 (ja) 2007-05-16
US20080146836A1 (en) 2008-06-19
IS2231B (is) 2007-04-15
CA2397583C (en) 2010-11-09
DE60015796T2 (de) 2005-11-03
UA71649C2 (en) 2004-12-15
HK1048321A1 (en) 2003-03-28
IS6408A (is) 2002-06-06
US20030220303A1 (en) 2003-11-27
SI1240172T1 (en) 2005-02-28
JP2003516407A (ja) 2003-05-13
ATE282043T1 (de) 2004-11-15
US20070021393A1 (en) 2007-01-25
EP1240172A1 (en) 2002-09-18
US6841698B2 (en) 2005-01-11
EP1240172B1 (en) 2004-11-10
US6576626B2 (en) 2003-06-10
AU2036401A (en) 2001-06-18
CA2397583A1 (en) 2001-06-14
HK1053125A1 (en) 2003-10-10
CZ20021983A3 (cs) 2002-11-13
IL149840A0 (en) 2002-11-10
US20050137414A1 (en) 2005-06-23
AU780459B2 (en) 2005-03-24
PL201789B1 (pl) 2009-05-29
NO329595B1 (no) 2010-11-22

Similar Documents

Publication Publication Date Title
AR030541A1 (es) Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica
AR015157A1 (es) DERIVADOS DEL ÁCIDO 5-ALQUIL-2-ARILAMINOFENILÁCETICO, COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE, SU USO EN LA MANUFACTURA DE UN MEDICAMENTO Y MÉTODO DE PREPARACIoN DEL MISMO
TR199500826A2 (tr) Multipl ünite tablet doz formu 2.
UY27092A1 (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
ES2160640T3 (es) Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos.
CR7362A (es) Formulaciones farmaceuticas de derivado de platino
UY27273A1 (es) Solución oral de arilpiprazol
ES2108371T3 (es) Nuevos derivados de estradieno de 11-benzaldoxima, procedimientos para su produccion y farmacos conteniendo estos compuestos.
ES2108425T3 (es) Analogos de atp sustituidos con n-alquilo-2.
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
ECSP055738A (es) PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL
DK0600079T3 (da) Oral 1alpha-hydroxyprævitamin D
ES2055860T3 (es) Derivados 2-aminopirimidinona.
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
AR019853A1 (es) Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci
ES2176106A1 (es) Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
PT101725A (pt) Processo para a preparacao de um composto de diarilo anti-aterosclerotico e de composicoes farmaceuticas que o contem
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
AR016973A1 (es) Uso de aminometil-cromanos sustituidos para la produccion de un medicamento util para el tratamiento de enfermedades neurodegenerativas y para el estimulode la regeneracion neuronal
AR033350A1 (es) Acidos (aminopropil) metilfosfinicos, su uso para la manufactura de medicamentos, formulacion farmaceutica, e intermediarios
AR001769A1 (es) Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación
ES2139965T3 (es) Benzoilguanidinas sustituidas con grupos de caracter basico, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
NO950134L (no) Formuleringer for oralt administrerte farmasöytiske midler
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.

Legal Events

Date Code Title Description
FG Grant, registration